Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44 Page 45 Page 46 Page 47 Page 48 Page 49 Page 50 Page 51 Page 52 Page 53 Page 54 Page 55 Page 56 Page 57 Page 58 Page 59 Page 60 Page 61 Page 62 Page 63 Page 6459 msfocusmagazine.org The submission to the European Medicines Agency is based on results from three Phase III clinical trials – CLARITY, CLARITYextension, and ORACLE MS – and the Phase II ONWARD trial. In these trials, treatment with oral cladribine significantly reduced relapse rates and the risk of disability progression and development of new MS lesions, compared to placebo. Together with interim, long-term follow-up results from the prospective registry PREMIERE, the new MAA also comprises follow-up data of more than 10,000 patient years of exposure, with some patients having a follow-up period surpassing eight years. According to Dr. Thrower, many clinicians in the U.S. are awaiting the decision of the European Medicines Agency. A positive decision could lead EMD Serono/Merck to resubmit a NDA to the FDA. Question asked: How do you cope with fatigue? Josephine Nakamura: I listen to my body, sit, relax, watch TV, or sleep. If you are fatigued, the best thing to do is to nap and refresh. I do all my cleaning in the morning, knowing that, by afternoon, I will not be able to do much more. Everyone is different, but to me this is the only way for me to cope. Over the years I have listened more, been more lenient with myself, and learned not to judge. Sonia Ewers: Knowing what I can or cannot do and not pushing too hard. I know that if I push, I will regret it. As my fiancé tells me, “This disease is not your fault and if you need a nap, then nap.” It doesn't always refresh me, but it’s better than completely falling apart from not doing it.